Oscar Health (OSCR) AI Stock Analysis

• Market Cap: $3.94B
• Dividend Yield: N/A
• Average Volume (3M): 33.58M
• Price to Earnings (P/E): 49.6
• Beta (1Y): 0.93
• Revenue Growth: 48.29%
• EPS Growth: -1436.25%
• Country: US
• Employees: 2,400
• Sector: Healthcare
• Sector Strength: 38
• Industry: Medical - Healthcare Plans
• EPS (TTM): -0.89
• Shares Outstanding: 219,163,000
• 10 Day Avg. Volume: 21,439,880
• 30 Day Avg. Volume: 33,579,313
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: 1.47
• Enterprise Value/Revenue: 0.57
• Enterprise Value/Gross Profit: 0.57
• Enterprise Value/Ebitda: 29.19
• 1Y Price Target: $11.94
• Price Target Upside: -22.77% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 9

• Rating: 69 Neutral
• Price Target: $16.50 ▲(6.73% Upside)

Oscar Health's overall stock score is driven by strong financial performance and strategic initiatives highlighted in the earnings call. However, technical analysis and valuation present challenges, with bearish momentum and a negative P/E ratio. The company's optimism for future profitability and strategic growth initiatives are positive, but short-term financial challenges remain.

Positive Factors

Membership Growth

The company's enrollment grew by 13% during the open enrollment period, surpassing market growth.

Revenue Guidance

Higher starting paid membership allowed OSCR to maintain direct revenue guidance while assuming that the continuous SEP for those below 150% of FPL ends.

Negative Factors

Enrollment Decline

OSCR's main geographic markets, representing a significant portion of its members, are expected to face large enrollment declines, affecting the company's revenue and operating margin.

Financial Performance

OSCR lowered 2025 EBIT by $500mn from a gain of $225-275mn to a loss of $200-300mn due to updated Risk Adjustment Reports from Wakely that show higher morbidity nationwide.

Market Risks

The expiration of enhanced advanced premium tax credits and regulatory crackdowns could lead to adverse risk pool shifts and structurally lower margins.

Pricing Strategy

The pricing strategy for Oscar Health, Inc. does not appear adequate to produce stable margins in the current year.

Oscar Health Business Overview & Revenue Model

Company Description

Oscar Health, Inc. provides health insurance products and services in the United States. The company offers Individual & Family, Small Group, and Medicare Advantage plans, as well as +Oscar, a technology driven platform designed to help providers and payor clients to engage with members and patients. It also provides reinsurance products. The company was formerly known as Mulberry Health Inc. and changed its name to Oscar Health, Inc. in January 2021. Oscar Health, Inc. was incorporated in 2012 and is headquartered in New York, New York.

How the Company Makes Money

Oscar Health makes money primarily through the collection of premiums from its members who enroll in its health insurance plans. The company's revenue streams include individual and family plans, small group plans, and Medicare Advantage plans. Oscar Health receives payments from members or sponsors, such as employers, who provide health insurance coverage. Additionally, the company may receive government subsidies for certain plans, particularly those offered under the Affordable Care Act. Oscar also generates revenue by managing healthcare utilization and costs effectively, as it shares in the savings if the cost of medical claims is lower than expected under value-based care arrangements. Partnerships with healthcare providers and a focus on preventive care and telemedicine also contribute to managing expenses and improving profitability.

Oscar Health Financial Statement Overview

Summary

Oscar Health exhibits a positive financial trajectory, with substantial revenue growth, improving profitability metrics, and strong cash flow generation. The balance sheet is solid, with low leverage and improving equity. Despite some areas needing improvement, such as the equity ratio, the company is on a strong financial footing.

Income Statement

Oscar Health has demonstrated a strong revenue growth trajectory, with a significant increase in total revenue from $4.1 billion in 2022 to $10.08 billion in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains robust at 100%, indicating efficient cost management. Net profit margin has improved from negative figures to 1.22% in TTM 2025, showing progress towards profitability. EBIT and EBITDA margins have also improved, reflecting better operational efficiency.

Balance Sheet

The company's balance sheet shows a solid equity base, with stockholders' equity rising from negative in 2020 to $1.33 billion in TTM 2025. The debt-to-equity ratio is low at 0.22, indicating conservative leverage. Return on equity has turned positive, reflecting enhanced profitability. However, the equity ratio is at 22.81%, suggesting potential room for improvement in equity financing.

Cash Flow

Oscar Health has shown strong cash flow generation, with free cash flow increasing from negative figures to $1.19 billion in TTM 2025. The free cash flow to net income ratio is healthy, indicating efficient cash management. Operating cash flow to net income ratio is high, demonstrating the company's ability to convert earnings into cash effectively.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	9.18B	5.86B	4.13B	1.92B	589.64M
Gross Profit	9.18B	5.86B	4.13B	1.92B	589.64M
EBITDA	89.31M	-212.00M	-572.17M	-551.25M	-390.98M
Net Income	25.43M	-270.73M	-606.27M	-572.61M	-406.82M
Balance Sheet
Total Assets	4.84B	3.60B	4.53B	3.32B	2.27B
Cash, Cash Equivalents and Short-Term Investments	2.15B	2.56B	2.96B	1.69B	1.19B
Total Debt	299.56M	298.78M	298.00M	0.00	142.49M
Total Liabilities	3.82B	2.80B	3.63B	440.02M	3.57B
Stockholders Equity	1.01B	803.97M	890.38M	1.39B	-1.30B
Cash Flow
Free Cash Flow	950.30M	-297.74M	351.34M	-207.63M	208.71M
Operating Cash Flow	978.19M	-272.16M	380.35M	-181.75M	222.73M
Investing Cash Flow	-1.39B	577.19M	-226.52M	-774.51M	-344.71M
Financing Cash Flow	68.39M	6.45M	301.11M	1.24B	611.71M

Oscar Health Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.46
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSCR, the sentiment is Positive. The current price of 15.46 is above the 20-day moving average (MA) of 14.41, below the 50-day MA of 15.75, and above the 200-day MA of 15.04, indicating a neutral trend. The MACD of -0.38 indicates Negative momentum. The RSI at 53.27 is Neutral, neither overbought nor oversold. The STOCH value of 90.01 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSCR.

Oscar Health Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HUM	75 Outperform	$32.07B	20.47	9.03%	1.33%	9.88%	-7.25%
OSCR	69 Neutral	$3.94B	49.61	-14.04%	―	48.29%	-1436.25%
MOH	65 Neutral	$8.50B	7.74	23.93%	―	16.12%	10.99%
CNC	58 Neutral	$12.57B	6.33	7.50%	―	12.96%	-23.25%
ALHC	55 Neutral	$2.87B	―	-38.50%	―	49.46%	66.89%
Sector *	51 Neutral	$7.35B	-0.20	-44.53%	2.35%	30.18%	-1.17%
CLOV	50 Neutral	$1.11B	―	-12.59%	―	-4.87%	66.16%

Oscar Health Corporate Events

Oscar Health Holds 2025 Annual Stockholders Meeting

On June 4, 2025, Oscar Health, Inc. held its 2025 Annual Meeting of Stockholders, where a quorum was established with 825,961,296 votes represented. During the meeting, nine directors were elected, and the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for 2025 was ratified. Additionally, the compensation of the company’s named executive officers was approved on an advisory basis, indicating shareholder support for the company’s leadership and financial oversight.

The most recent analyst rating on (OSCR) stock is a Sell with a $13.50 price target. To see the full list of analyst forecasts on Oscar Health stock, see the OSCR Stock Forecast page.